A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Abiraterone acetate (Primary) ; Niraparib (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 07 Dec 2018 Planned End Date changed from 25 Sep 2026 to 25 Feb 2025.
- 19 Nov 2018 Status changed from planning to not yet recruiting.
- 06 Nov 2018 New trial record